279 related articles for article (PubMed ID: 33438291)
1. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy.
Kalaria S; Williford S; Guo D; Shu Y; Medlin C; Li M; Yeung SYA; Ali F; Jean W; Gopalakrishnan M; Heavner M
Pharmacotherapy; 2021 Feb; 41(2):205-211. PubMed ID: 33438291
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
[TBL] [Abstract][Full Text] [Related]
3. A prospective, real-world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADRE-02).
Kalaria SN; Armahizer M; McCarthy P; Badjatia N; Gobburu JV; Gopalakrishnan M
Br J Clin Pharmacol; 2021 Nov; 87(11):4375-4385. PubMed ID: 33855736
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
Wenzler E; Butler D; Tan X; Katsube T; Wajima T
Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
[TBL] [Abstract][Full Text] [Related]
5. A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01).
Kalaria SN; Armahizer M; McCarthy P; Badjatia N; Gobburu JV; Gopalakrishnan M
Clin Transl Sci; 2020 Sep; 13(5):950-959. PubMed ID: 32223067
[TBL] [Abstract][Full Text] [Related]
6. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update.
Hoff BM; Maker JH; Dager WE; Heintz BH
Ann Pharmacother; 2020 Jan; 54(1):43-55. PubMed ID: 31342772
[No Abstract] [Full Text] [Related]
8. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Peng Y; Cheng Z; Xie F
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
[TBL] [Abstract][Full Text] [Related]
9. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
[TBL] [Abstract][Full Text] [Related]
10. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658965
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
He S; Cheng Z; Xie F
Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.
Dubinsky S; Watt K; Saleeb S; Ahmed B; Carter C; Yeung CHT; Edginton A
Clin Pharmacokinet; 2022 Feb; 61(2):189-229. PubMed ID: 34846703
[TBL] [Abstract][Full Text] [Related]
13. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
[TBL] [Abstract][Full Text] [Related]
15. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
[TBL] [Abstract][Full Text] [Related]
16. Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy.
Wang C; Chen J; Yang B; Li S; Zhang Y; Chen L; Wang T; Dong Y
Pharmacotherapy; 2023 Mar; 43(3):180-188. PubMed ID: 36714991
[TBL] [Abstract][Full Text] [Related]
17. Principles of antibacterial dosing in continuous renal replacement therapy.
Choi G; Gomersall CD; Tian Q; Joynt GM; Freebairn R; Lipman J
Crit Care Med; 2009 Jul; 37(7):2268-82. PubMed ID: 19487930
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
Novy E; Abdul-Aziz MH; Cheng V; Burrows F; Buscher H; Corley A; Diehl A; Gilder E; Levkovich BJ; McGuinness S; Ordonez J; Parke R; Parker S; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0120123. PubMed ID: 38063399
[TBL] [Abstract][Full Text] [Related]
19. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.
Broeker A; Wicha SG; Dorn C; Kratzer A; Schleibinger M; Kees F; Heininger A; Kees MG; Häberle H
Crit Care; 2018 Dec; 22(1):341. PubMed ID: 30558639
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
Gatti M; Giannella M; Raschi E; Viale P; De Ponti F
J Antimicrob Chemother; 2021 Jan; 76(1):199-205. PubMed ID: 33057628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
